Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $560,840.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 4,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $140.21, for a total transaction of $560,840.00. Following the completion of the transaction, the insider owned 200,000 shares of the company’s stock, valued at $28,042,000. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Thursday, July 9th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00.
• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The stock was sold at an average price of $110.00, for a total transaction of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $785,760.00.

Billiontoone Stock Down 38.9%

BLLN stock opened at $91.65 on Friday. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $150.44. The company has a market capitalization of $4.21 billion and a price-to-earnings ratio of 130.93. The business’s 50 day moving average price is $116.61 and its two-hundred day moving average price is $94.28. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting analysts’ consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 12.84% and a net margin of 8.04%. As a group, analysts forecast that Billiontoone, Inc. will post 0.92 earnings per share for the current fiscal year.

Billiontoone News Roundup

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Strong quarterly revenue: BillionToOne reported second-quarter revenue of $109.45 million and adjusted earnings of $0.15 per share, matching Wall Street expectations. The company also reiterated full-year 2026 revenue guidance of $450 million to $465 million, indicating continued growth. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
• Positive Sentiment: Analysts remain constructive: BTIG Research and JPMorgan Chase both maintained bullish ratings, using “buy” and “overweight,” respectively. Each firm lowered its price target to $130, which still implies substantial upside from the referenced share price. Benzinga analyst price-target reports
• Neutral Sentiment: Investor focus is on guidance: Coverage of the results highlighted that revenue surged, but management did not increase its full-year forecast. The lack of an outlook raise appears to have disappointed investors who had expected stronger guidance following the quarter. BillionToOne sinks as outlook unchanged despite surging revenue
• Negative Sentiment: Price targets were cut: JPMorgan reduced its target from $145 to $130, while BTIG lowered its target from $142 to $130. Although both firms kept positive ratings, the reductions signal more limited near-term expectations and added pressure to the stock. Benzinga analyst price-target reports
• Negative Sentiment: Insider selling adds an overhang: CEO Oguzhan Atay sold 45,000 shares worth approximately $6.17 million, while insider Shan Riku Sakakibara sold 4,000 shares for about $561,000. The transactions were made under pre-arranged Rule 10b5-1 plans, reducing their signaling value but potentially weighing on sentiment. Billiontoone insider selling reports

Hedge Funds Weigh In On Billiontoone

A number of hedge funds have recently bought and sold shares of the company. Baillie Gifford & Co. bought a new position in Billiontoone in the 4th quarter valued at approximately $103,786,000. Emerald Mutual Fund Advisers Trust increased its holdings in shares of Billiontoone by 11.9% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock worth $10,436,000 after purchasing an additional 14,072 shares in the last quarter. Perceptive Advisors LLC raised its stake in shares of Billiontoone by 26.1% in the first quarter. Perceptive Advisors LLC now owns 91,812 shares of the company’s stock worth $7,248,000 after purchasing an additional 19,000 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Billiontoone in the fourth quarter worth $13,373,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Billiontoone during the first quarter valued at $1,539,000.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BLLN shares. Guggenheim started coverage on shares of Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. BTIG Research lowered their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. dropped their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $126.71.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.